John Sourbeer
Stock Analyst at UBS
(0)
# 4018
Out of 5,218 analysts
46
Total ratings
50.00%
Success rate
-3.19%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
West Pharmaceutical ... | Upgrades: Buy | 350 390 | 330.02 | 18.17% | 3 | Dec 12, 2024 | |
Pacific Biosciences | Downgrades: Neutral | 2 | 1.96 | 2.04% | 3 | Nov 11, 2024 | |
Illumina | Maintains: Neutral | 133 145 | 143.9 | 0.76% | 3 | Nov 5, 2024 | |
QuidelOrtho | Upgrades: Neutral | 42 50 | 41.37 | 20.86% | 2 | Sep 19, 2024 | |
Singular Genomics Sy... | Maintains: Neutral | 12 15 | 20 | -25% | 2 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 15 17 | 7.69 | 121.07% | 4 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 452 480 | 345.86 | 38.78% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 7 8 | 2.27 | 230.4% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 94 102 | 57.61 | 77.05% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 58 64 | 63.08 | 0.67% | 6 | Feb 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 50 44 | 45.37 | -4.65% | 3 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 7 3 | n/a | n/a | 2 | Oct 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 50 | 14.18 | 252.61% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 68 | n/a | n/a | 1 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 270 | 208.16 | 29.71% | 1 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 142 128 | 113.45 | 12.83% | 2 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 13 4 | n/a | n/a | 2 | Mar 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 22 | 23.46 | -6.22% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 23 | n/a | n/a | 1 | Feb 22, 2021 |